A recent integrated pan-cancer analysis, validated with breast cancer data, has identified SEC13 homolog as a potential prognostic biomarker and immunotherapy target. The study, published in a peer-reviewed journal, analyzed expression data from multiple cancer types using databases like TCGA and GEO.
SEC13, a core scaffold of the GATOR2 complex, regulates mTORC1 signaling and endoplasmic reticulum homeostasis, influencing cellular metabolism. The analysis found elevated SEC13 expression across various solid tumors, including breast, lung, and colorectal cancers, correlating with poorer patient outcomes.
In breast cancer validation, high SEC13 levels were associated with reduced overall survival and immune infiltration patterns, suggesting its role in tumor microenvironment modulation. The researchers propose SEC13 as a candidate for targeted immunotherapy, though further clinical studies are needed.
This finding highlights SEC13's dual role in cancer metabolism and immune evasion, offering a new avenue for therapeutic development. The study was conducted by a team of researchers from multiple institutions, with data current as of early 2026.
